History

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Scroll down and load more to see the history of Celgene unfold. The timeline will take you from our founding through our exponential growth over the past three decades.

1986
David Stirling, Ph.D. and Sol Barer, Ph.D. plant the seed that will become Celgene.
David Stirling, Ph.D. and Sol Barer, Ph.D. plant the seed that will become Celgene.
Celgene becomes an independent biotechnology company.
Celgene becomes an independent biotechnology company.
1987
Celgene IPO (initial public offering).
Celgene IPO (initial public offering).
Load More